Manidón Retard

Verapamil Hydrochloride, the active ingredient in Manidón Retard, is a calcium channel blocker presented as an extended‑release tablet for oral use. It is employed to manage hypertension, angina pectoris and supraventricular arrhythmias in adult patients, acting as both an antiarrhythmic and antihypertensive agent.

GNH USA supplies Manidón Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for import and distribution. Products are shipped in secure packaging with temperature control as required.

Verapamil is a calcium channel blocker used in cardiovascular disease management.

- Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. - Angina pectoris: decreases myocardial oxygen demand and relieves chest‑pain episodes. - Supraventricular arrhythmias: helps restore normal sinus rhythm and control ventricular rate.

Verapamil may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Dizziness: transient orthostatic changes. - Headache: vasodilatory effect. - Peripheral edema: fluid accumulation in lower limbs. - Flushing: transient cutaneous vasodilation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Bradycardia: markedly slowed heart rate. - Hypotension: severe drop in blood pressure. - Heart block: impairment of AV nodal conduction. - Atrioventricular conduction disturbances: risk of advanced block. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood pressure: check for excessive hypotension. - Assess cardiac conduction: perform ECG before and during therapy. - Review concomitant beta‑blocker use: risk of additive bradycardia. - Adjust dose in hepatic impairment: reduced clearance may increase exposure. - Avoid abrupt discontinuation: may precipitate rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture.

Verapamil interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Beta‑blockers: risk of severe bradycardia and AV block. - Diltiazem or other verapamil products: additive cardiac depression. - Digoxin: increased serum digoxin levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevated verapamil concentrations. - Simvastatin: heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Diuretics: potential electrolyte disturbances, especially potassium loss. - NSAIDs: may attenuate antihypertensive effect. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced verapamil exposure.